Spyglass Pharma, Inc. (NASDAQ:SGP) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Six analysts give SGP an average "Moderate Buy" (five buys, one hold) with a 12‑month average price target of $45.00 and individual targets roughly in the $37–$62 range.
• Insider purchase: Director Ra Capital Management bought 3,690,000 shares at $16.00 each (~$59.04M) in February, increasing its stake to about 5.97M shares (a 162.1% rise).
• Recent results and stock level: Spyglass reported Q EPS of ($5.72), beating estimates of ($6.61), and SGP trades near $23.52 with a 12‑month range of $20.15–$32.44 (50‑day MA ≈ $25.57).

Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $45.00.

A number of equities research analysts have commented on the company. Stifel Nicolaus assumed coverage on Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a "buy" rating and a $42.00 price target on the stock. Wall Street Zen lowered Spyglass Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, March 28th. Jefferies Financial Group assumed coverage on Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a "buy" rating and a $62.00 price target on the stock. Citigroup assumed coverage on Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a "buy" rating and a $42.00 price target on the stock. Finally, HC Wainwright assumed coverage on Spyglass Pharma in a research report on Tuesday, March 10th. They issued a "buy" rating and a $37.00 price target on the stock.

Spyglass Pharma Stock Performance

Shares of SGP stock opened at $23.52 on Friday. The stock's fifty day moving average price is $25.57. Spyglass Pharma has a twelve month low of $20.15 and a twelve month high of $32.44.

Spyglass Pharma (NASDAQ:SGP - Get Free Report) last released its quarterly earnings results on Thursday, March 26th. The company reported ($5.72) EPS for the quarter, beating analysts' consensus estimates of ($6.61) by $0.89.

Insider Activity at Spyglass Pharma

In related news, Director Ra Capital Management, L.P. purchased 3,690,000 shares of Spyglass Pharma stock in a transaction on Monday, February 9th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $59,040,000.00. Following the transaction, the director owned 5,966,439 shares of the company's stock, valued at approximately $95,463,024. This represents a 162.10% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Spyglass Pharma Company Profile

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.